NCT06285019 2024-02-29
Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma
Fudan University
Phase 2 Unknown
Clinical Trials
155 trialsNCT05178043 2024-02-22
GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma
Suzhou Kintor Pharmaceutical Inc,
Phase 2 Unknown
NCT06210334 2024-02-20
HAI-TL
Eastern Hepatobiliary Surgery Hospital
Phase 2 Unknown
NCT05962450 2024-01-16
Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy
Beijing YouAn Hospital
Phase 2 Unknown
NCT06085976 2023-10-17
Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.
Clinica Universidad de Navarra, Universidad de Navarra
Phase 2 Unknown
NCT05010434 2023-09-21
Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT06001567 2023-09-14
Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAIC
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Unknown
NCT03447951 2023-09-13
OASES
Gongwin Biopharm Co., Ltd.
Phase 2 Unknown
NCT06031480 2023-09-11
FAITH
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT06029829 2023-09-08
The Clinical Significance of Peripheral Blood T Lymphocyte PD-1 Expression and T Cell Subset Distribution.
China Three Gorges University, Yichang, China
Phase 2 Unknown
NCT04135690 2023-08-15
HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial
Sun Yat-sen University
Phase 2 Unknown
NCT05099848 2023-08-15
A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma
Shandong Cancer Hospital and Institute
Phase 2 Unknown
NCT05971199 2023-08-02
Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT05576909 2023-07-13
Donafenib Combined With Hepatic Artery Chemoembolization for Perioperative Treatment of Liver Transplantation
Beijing Tsinghua Chang Gung Hospital
Phase 2 Unknown
NCT05925413 2023-06-29
Cadonilimab Plus TACE in Patients With Intermediate-stage Unresectable Hepatocellular Carcinoma
Eastern Hepatobiliary Surgery Hospital
Phase 2 Unknown
NCT05897268 2023-06-27
CASTLE-10
Fudan University
Phase 2 Unknown
NCT04962958 2023-06-22
Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT05903456 2023-06-15
Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT04930315 2023-06-13
CAPT
Zhejiang University
Phase 2 Unknown
NCT05886465 2023-06-02
HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial
Sun Yat-sen University
Phase 2 Unknown
NCT05883176 2023-05-31
B-TACE
Sun Yat-sen University
Phase 2 Unknown
NCT05872841 2023-05-24
H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05134532 2023-04-26
HCC
CHA University
Phase 2 Unknown
NCT04368078 2023-03-29
Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05048017 2023-03-29
Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04663035 2023-03-22
Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC
Sun Yat-sen University
Phase 2 Unknown
NCT05616390 2023-03-21
Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown
NCT05760430 2023-03-08
The Synergistic Effect of Portal Venous Supply Control and Immunotherapy in Hepatocellular Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT05760599 2023-03-08
Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T
Sun Yat-sen University
Phase 2 Unknown
NCT04992143 2023-02-16
TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC
First Affiliated Hospital of Zhejiang University
Phase 2 Unknown
NCT05029973 2023-02-08
HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05312216 2023-01-26
Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma
Zhejiang University
Phase 2 Unknown
NCT04213118 2023-01-17
ALTER-H-004
First Affiliated Hospital Xi'an Jiaotong University
Phase 2 Unknown
NCT05617430 2022-11-15
Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT04718909 2022-11-10
REGSIN
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Unknown
NCT05555316 2022-09-26
TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT05550025 2022-09-22
TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT05545124 2022-09-19
Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence
Henan Cancer Hospital
Phase 2 Unknown
NCT05493332 2022-08-18
HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT04174781 2022-06-09
Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC
Zhejiang University
Phase 2 Unknown
NCT05396937 2022-05-31
Efficacy and Safety of T+A+RAD in HCC
Fudan University
Phase 2 Unknown
NCT05111366 2022-05-04
ALTER-H006
Hunan Provincial People's Hospital
Phase 2 Unknown
NCT05171439 2022-04-14
Surufatinib in Advanced Hepatocellular Carcinoma Based on Single-cell Sequencing of Tumor Samples
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Unknown
NCT05311319 2022-04-05
HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection
Fudan University
Phase 2 Unknown
NCT05282433 2022-03-16
Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma
Zhongnan Hospital
Phase 2 Unknown
NCT05240404 2022-02-15
Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma
Xiangya Hospital of Central South University
Phase 2 Unknown
NCT05213637 2022-02-07
Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical Resection
Chinese PLA General Hospital
Phase 2 Unknown
NCT03067493 2022-01-26
RAMEC
Sun Yat-sen University
Phase 2 Unknown
NCT03973112 2022-01-12
A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients
Shanghai Henlius Biotech
Phase 2 Unknown